📰 **Telix Presents Phase 2 OPTIMAL-PSMA Dosimetry Data For TLX597-Tx In Prostate Cancer Treatment **

(RTTNews) - Telix Pharmaceuticals Limited (TLX), a commercial-stage biopharmaceutical company, on Thursday presented dosimetry data from the Phase 2 OPTIMAL-PSMA trial for TLX597-Tx in treating metastatic castration-resistant prostate cancer (mCRPC).

🔗 https://www.nasdaq.com/articles/telix-presents-phase-2-optimal-psma-dosimetry-data-tlx597-tx-prostate-cancer-treatment

#markets #news